...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Targeting Aryl hydrocarbon receptor for next-generation immunotherapies: Selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs)
【24h】

Targeting Aryl hydrocarbon receptor for next-generation immunotherapies: Selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs)

机译:靶向下一代免疫检查的芳基烃受体:选择性调节剂(SAHRMS)与快速代谢的配体(RMAHRL)

获取原文
获取原文并翻译 | 示例
           

摘要

Aryl Hydrocarbon Receptor (AhR) constitutes a major network hub of genomic and non-genomic signaling pathways, connecting host's immune cells to environmental factors. It shapes innate and adaptive immune processes to environmental stimuli with species-, cell- and tissue-type dependent specificity, Although an ever increasing number of studies has thrust AhR into the limelight as attractive target for the development of next-generation immunotherapies, concerns exist on potential safety issues associated with small molecule modulation of the receptor. Selective AhR modulators (SAhRMs) and rapidly metabolized AhR ligands (RMAhRLs) are two classes of receptor agonists that are emerging as interesting lead compounds to bypass AhR-related toxicity in favor of therapeutic effects. In this article, we discuss SAhRMs and RMAhRLs reported in literature, covering concepts underlying their definitions, specific binding modes, structure-activity relationships and AhR-mediated functions. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:芳基烃受体(AHR)构成基因组和非基因组信号传导途径的主要网络枢纽,将宿主的免疫细胞连接到环境因素。它以物种,细胞和组织型依赖特异性为环境刺激的先天和适应性免疫过程塑造了环境刺激,尽管越来越多的研究已经将AHR推入敏捷,作为开发下一代免疫检查的有吸引力的目标,存在担忧论与受体小分子调节相关的潜在安全问题。选择性AHR调节剂(SAHRMS)和迅速代谢的AHR配体(RMAHRL)是两类受体激动剂,其是逐步绕过AHR相关的毒性,以支持治疗效果。在本文中,我们讨论了文学中报告的SAHRMS和RMAHRL,涵盖了其定义,特异性结合模式,结构 - 活动关系和AHR介导的功能的概念。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号